StockMarketWire.com - GlaxoSmithKline said that the European Medicines Agency's Committee had issued a 'positive' opinion recommending two new methods for administering the company's asthma treatment.

The agency recommended a pre-filled pen and a pre-filled safety syringe, to be taken once every four weeks.

If approved, the two new Nucala options would offer healthcare professionals the choice of prescribing at-home administration for appropriate patients.

The original lyophilised powder version remained available for administration in clinic by a healthcare professional.

'A CHMP (Committee for Medicinal Products for Human Use positive opinion is one of the final steps before marketing authorisation is granted by the European Commission,' the company said.




At 9:35am: [LON:GSK] GlaxoSmithKline PLC share price was -20.8p at 1528.4p



Story provided by StockMarketWire.com